Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PhaseRx, Inc.
Public Company Financings: Rhythm and OptiNose are the 30th and 31st initial public offerings of 2017. Also, reverse mergers add two more newly public firms, Valeant raises $1bn to pay down more debt, and PhaseRx and Trevena cut jobs.
Having ditched silence RNA in 2012, PhaseRx president and CEO Dr Robert Overell explains to Mike Ward, global director of content at Informa Pharma Intelligence’s insights portfolio, how delivering messenger RNA inside diseased cells may revolutionize and grow the current $4bn enzyme replacement market.
After biopharma initial public offerings in the US during 2016 outperformed the prior year’s IPOs, expect more of the same in 2017: fewer, but higher quality offerings at lower IPO share prices to keep values at acceptable levels for experienced health care investors.
Motif Bio and TiGenix were the 29th and 30th biopharma IPOs in 2016 with the only first-time offerings for November and so far in December, but looking at performance so far this year, IPOs by therapeutics firms in 2016 continue to outperform 2015 offerings.
- Drug Delivery
- Antisense, Oligonucleotides
- Large Molecule